Clinical Evidence: The SURMOUNT-1 Trial
Zepbound’s efficacy was established in the landmark SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022; 387:205-216, DOI: 10.1056/NEJMoa2206038), which enrolled 2,539 adults with obesity (BMI $\ge 30$) or overweight (BMI $\ge 27$) with at least one weight-related condition, excluding diabetes. Participants were randomized 1:1:1:1 to once-weekly tirzepatide (5 mg, 10 mg, or 15 mg) or placebo over 72 weeks:
| Tirzepatide Dose | Mean Weight Loss (%) | Absolute Loss (lbs) | ≥15% Loss Rate | ≥20% Loss Rate | ≥25% Loss Rate |
|---|---|---|---|---|---|
| 5 mg weekly | -15.0% | -35.5 lbs (-16.1 kg) | 50.0% | 30.0% | 15.3% |
| 10 mg weekly | -19.5% | -48.9 lbs (-22.2 kg) | 69.0% | 50.1% | 31.6% |
| 15 mg weekly | -20.9% | -52.0 lbs (-23.6 kg) | 68.6% | 56.7% | 36.2% |
| Placebo | -3.1% | -5.3 lbs (-2.4 kg) | 9.0% | 4.1% | 1.3% |
Zepbound Stepwise Dosage & Titration Protocol
Zepbound is supplied in single-dose, pre-filled auto-injector pens with integrated hidden needles. Treatment begins at a low initiation dose and steps up every 4 weeks to optimize clinical response and minimize gastrointestinal side effects:
| Titration Step | Schedule | Weekly Dose | Clinical Role |
|---|---|---|---|
| Step 1 (Initiation) | Weeks 1–4 | 2.5 mg weekly | Gastrointestinal adaptation phase (not for chronic maintenance) |
| Step 2 (Therapeutic 1) | Weeks 5–8 | 5.0 mg weekly | Initial therapeutic dose; significant appetite suppression |
| Step 3 (Escalation 1) | Weeks 9–12 | 7.5 mg weekly | Intermediate titration step toward higher maintenance |
| Step 4 (Therapeutic 2) | Weeks 13–16 | 10.0 mg weekly | Advanced therapeutic maintenance tier |
| Step 5 (Escalation 2) | Weeks 17–20 | 12.5 mg weekly | Near-maximal incretin receptor stimulation |
| Step 6 (Maximum) | Week 21 onward | 15.0 mg weekly | Maximum approved maintenance dose for chronic weight loss |
Experience Dual GIP/GLP-1 Weight Management
Flat $1,199/mo rate across all six doses. Save up to $100 on your first order. 24-hour doctor approval and cold-chain insulated home delivery.
See If You QualifySafety Profile, Boxed Warning & Adverse Reactions
Zepbound carries an FDA Boxed Warning for Thyroid C-Cell Tumors. In female and male rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas). It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
BOXED WARNING & PRECAUTIONS
- Contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC).
- Contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Contraindicated in patients with serious hypersensitivity to tirzepatide.
- Oral Contraceptive Interaction: Advise patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after initiation and 4 weeks after each dose escalation.
In SURMOUNT-1, the most common adverse events ($\ge 5\%$) across tirzepatide doses were gastrointestinal: nausea (24.6%–33.3% vs 9.5% placebo), diarrhea (18.7%–23.0% vs 7.3%), vomiting (8.3%–12.2% vs 1.7%), constipation (11.1%–17.1% vs 5.8%), and dyspepsia (8.0%–10.2% vs 2.5%). Gastrointestinal symptoms were mostly mild to moderate and occurred primarily during dose escalation.
Zepbound vs. Wegovy: Landmark Head-to-Head Comparison
| Clinical Factor | Zepbound™ (Tirzepatide) | Wegovy® (Semaglutide 2.4mg) |
|---|---|---|
| Receptor Class | Dual GIP and GLP-1 receptor co-agonist | Single GLP-1 receptor agonist |
| Mean Weight Loss (Max Dose) | -20.9% (-52.0 lbs) in SURMOUNT-1 | -14.9% (-33.7 lbs) in STEP-1 |
| >=20% Weight Loss Rate | 56.7% of patients at 15mg | 32.0% of patients at 2.4mg |
| >=25% Weight Loss Rate | 36.2% of patients at 15mg | Not reported / <10% |
| Telehealth FX Monthly Rate | $1,199/mo flat across all doses | $899/mo flat across all doses |
| Introductory Savings | Save up to $100 on 1st order | Save up to $100 on 1st order |
Frequently Asked Questions
What is Zepbound and how does it differ from single GLP-1 medications?
Zepbound™ (tirzepatide) is an FDA-approved injectable medication for chronic weight management. Unlike single GLP-1 receptor agonists (such as Wegovy or Ozempic), Zepbound is a dual GIP and GLP-1 receptor co-agonist. By activating both metabolic pathways simultaneously, it achieves superior appetite suppression, enhanced metabolic rate, and significantly higher clinical weight loss (up to 20.9% in SURMOUNT-1).
How much does Zepbound cost through Telehealth FX?
Through Telehealth FX, authentic Zepbound is priced at a flat rate of $1,199 per month across all six dose levels (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg). First orders receive a discount saving up to $100 auto-applied at checkout ($1,099 for your first month). The fee includes your clinical consultation, titration monitoring, and free cold-chain express shipping with zero membership surcharges.
What were the primary weight loss results from the SURMOUNT-1 trial?
In the 72-week SURMOUNT-1 trial (NEJM 2022, n=2,539), adults taking tirzepatide achieved mean weight reductions of 15.0% at 5mg (35.5 lbs), 19.5% at 10mg (48.9 lbs), and 20.9% at 15mg (52.0 lbs) compared to 3.1% (5.3 lbs) for placebo (p<0.001). Over 91% achieved >=5% weight loss, and 36.2% lost 25% or more of their total body weight.
What is the Zepbound dose escalation schedule?
Zepbound begins with a starting dose of 2.5 mg once weekly for 4 weeks (initiation). Doses are increased in 2.5 mg increments every 4 weeks based on patient tolerance: 5.0 mg (weeks 5–8), 7.5 mg (weeks 9–12), 10.0 mg (weeks 13–16), 12.5 mg (weeks 17–20), and the maximum maintenance dose of 15.0 mg weekly from week 21 onward.
Does Zepbound interact with oral birth control pills?
Yes. Tirzepatide delays gastric emptying, which can transiently reduce the peak absorption (Cmax) of oral contraceptives. Patients using oral birth control pills are advised to add a barrier method (or switch to non-oral contraception) for 4 weeks after initiating treatment and for 4 weeks after each dose escalation.
Is Zepbound covered by HSA or FSA?
Yes. Zepbound is an FDA-approved clinical prescription for obesity and overweight management. All consultation and medication costs qualify under IRS Section 213(d) and can be reimbursed or paid with an HSA/FSA debit card.
Real Patient Reviews & Clinical Outcomes
"Dual GIP and GLP-1 targeting is remarkably more effective. Down 46 lbs on Zepbound with virtually zero nausea. Exceptional telehealth coordination."
"The flat price across dose increases made planning simple. Authentic Lilly autoinjector pens arrived in perfect cold-chain insulated packaging."
Start Your Zepbound Program Today
$1,199/mo flat rate across all doses. Save up to $100 on your first order. 24-hour doctor approval. Free cold-chain express shipping.
Claim $100 Off First Order